Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
0.5800
-0.0440 (-7.05%)
At close: Sep 4, 2025, 4:00 PM
0.5390
-0.0410 (-7.07%)
Pre-market: Sep 5, 2025, 5:11 AM EDT
Incannex Healthcare Revenue
Incannex Healthcare had revenue of $98.00K in the twelve months ending March 31, 2025. In the fiscal year ending June 30, 2024, Incannex Healthcare had annual revenue of $12.00K.
Revenue (ttm)
$98.00K
Revenue Growth
n/a
P/S Ratio
106.17
Revenue / Employee
$10,889
Employees
9
Market Cap
54.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 12.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 539.05K | -883.65K | -62.11% |
| Jun 30, 2021 | 1.42M | 1.01M | 240.67% |
| Jun 30, 2020 | 417.62K | 416.53K | 38,249.13% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IXHL News
- 9 days ago - Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder - GlobeNewsWire
- 13 days ago - Incannex Healthcare Authorizes $20 Million Share Repurchase Program - GlobeNewsWire
- 16 days ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update - Newsfile Corp
- 27 days ago - Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea - GlobeNewsWire
- 5 weeks ago - Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term - GlobeNewsWire
- 5 weeks ago - Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial - Benzinga
- 5 weeks ago - Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X - GlobeNewsWire
- 5 weeks ago - Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo - GlobeNewsWire